Despite the extensive research effort that has been made in the field, motor neuron diseases, namely, amyotrophic lateral sclerosis and spinal muscular atrophies, still represent an overwhelming cause of morbidity and mortality worldwide. Exogenous neural stem cell-based transplantation approaches have been investigated as multifaceted strategies to both protect and repair upper and lower motor neurons from degeneration and inflammation. Transplanted neural stem cells (NSCs) exert their beneficial effects not only through the replacement of damaged cells but also via bystander immunomodulatory and neurotrophic actions. Notwithstanding these promising findings, the clinical translatability of such techniques is jeopardized by the limited engraftment success and survival of transplanted cells within the hostile disease microenvironment. To overcome this obstacle, different methods to enhance graft survival, stability, and therapeutic potential have been developed, including environmental stress preconditioning, biopolymers scaffolds, and genetic engineering. In this review, we discuss current engineering techniques aimed at the exploitation of the migratory, proliferative, and secretive capacity of NSCs and their relevance for the therapeutic arsenal against motor neuron disorders and other neurological disorders.
Introduction
Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophies (SMAs) are severe diseases characterized by selective motor neuron degeneration. ALS is an incurable, progressive neurodegenerative disease characterized by loss of upper and lower motor neurons leading to irreversible muscular paralysis and eventually respiratory failure and death within 3 to 5 years after onset [1] . To date, only two approved therapies, riluzole and edaravone, with a minimal impact on survival, are available for ALS, along with supportive care (e.g., neurorehabilitation) [2, 3] . SMAs are inherited degenerative disorders affecting motor neurons of the anterior horns of spinal cord gray matter. Proximal 5q SMA results from homozygous mutations in the survival motor neuron 1 (SMN1) gene. Nusinersen, an antisense oligonucleotide that modulates the expression of SMN2, was recently approved as the first therapy for SMA 5q. However, no effective treatment is available for other types of SMA [4] .
Despite the variety of studies performed in this field, there are currently no valid therapeutic strategies capable of counteracting neuronal loss after its occurrence and regenerating the damaged central nervous system (CNS). Furthermore, the complex dynamics underlying the pathogenesis of motor neuron diseases (MNDs) and the relatively selective death of motor neurons remain elusive. Therefore, there exists an urgent need to cast a light over the cellular and molecular networks involved, to identify novel targets for drug development and to develop truly compelling therapeutic approaches. Clearly, to be applicable in MNDs, regenerative therapies should ultimately regulate or antagonize these complex pathways, thereby promoting the maintenance or restoration of motor neuron function [5] .
Neural Stem Cells
Neural stem cells (NSC) are self-renewing and multipotent cells that can differentiate into the three major neuroectodermal lineages: neurons, astrocytes, and oligodendrocytes. During the embryonic period, NSCs reside in the neural tube, the precursor of the mammalian CNS [6] , where they first differentiate into neuroepithelial cells and then into radial glial cells, the main NSCs during embryonic neurogenesis, located in the ventricular zone [6] . These stem cells proliferate and give rise to neuronal cells, which subsequently migrate radially from the ventricular zone to the cortical plate, where they settle to create the cerebral cortex [6] .
Past research has shown that neurogenesis continues during adult life in discrete regions of the mammalian CNS, thus suggesting the possibility of neuronal repair after injury or in neurological conditions [7] [8] [9] [10] . NSCs in the mammalian adult brain are located in the subventricular and subgranular zones of the hippocampal dentate gyrus and generate mature neuronal cells that appear to be involved in olfaction, learning, and memory processes [11, 12] . In humans, NSCs have been found in the subgranular zone of the hippocampus [13] . These findings, however, have lately been challenged by a report showing that the number of hippocampal neural progenitors significantly decreases in human brains after childhood [14] . Nevertheless, a recent work by Boldrini and colleagues further supported the former hypothesis, showing that a comparable number of neural progenitor cells (NPCs) and immature and mature neurons were observed in the dentate gyrus region of the brain throughout aging [15] . The precise amount and role of NSC replication and differentiation in the human adult brain, in particular in response to injury such as stroke or neurological disease, remains a matter of debate. Furthermore, cells in the spinal cord, located near the central canal, have been suggested to serve as NSCs, as they have been shown to be able to differentiate into neurons and glia cells in vitro [16] . This theory, however, is even more controversial than neurogenesis in the adult brain, and further research is needed in order to better elucidate the true role of these cells in humans.
Neural Stem Cells and Motor Neuron Diseases: Endogenous Neurogenesis
Since the therapeutic activation and guidance of endogenous NSCs in the brain and spinal cord could be exploited for reparative purposes, defining their presence, quantity, and functionality in the healthy and diseased adult human CNS is of paramount importance. Therefore, we believe that further research in this field is essential, particularly in a disease context.
In this respect, adult transgenic human mutant SOD1 (mSOD1) mice, the most frequently used ALS transgenic model, have been shown to exhibit alterations in the adult forebrain NSC niche, with NSCs showing more vulnerability to disease than NPCs [17] . The response of NSCs to mitogen was found to be impaired in mSOD1 symptomatic and presymptomatic mice, while the proliferation and differentiation abilities of neuroprogenitors were preserved throughout the course of disease, thus making NSCs potential targets for recruitment with pharmacological stimulation or a cell source for transplantation [17] . Additionally, Chi and colleagues analyzed the activation of NPCs following motor neuron degeneration in ALS-like transgenic mice carrying a nestin enhancer-driven LacZ reporter and SOD1 mutation [18] . These authors reported an increased number of LacZpositive NPCs in the spinal cord posterior horn with disease onset, while NPC proliferation in the ventral horn was only observed during disease progression. Conversely, the numbers of progenitors in the precentral brain cortex were increased at disease onset but not during progression, whereas no significant differences could be detected in the number of hippocampal NPCs. Notably, the NPCs in the ALS models gave rise to a neuronal population in response to neurodegenerative stimuli [18] . While this study is very interesting, its possible limitation resides in the technology used to reveal neurogenesis, based on LacZ staining, which carries a risk of false-positive results.
Although further research is needed to clarify the role of endogenous NSCs in MNDs, these findings provide interesting evidence that regenerative treatment of these disorders could be pursued by stimulating and enhancing de novo neurogenesis.
Notwithstanding these exciting results, ALS-induced compensatory neurogenesis in the CNS is not powerful enough to halt disease progression in affected animals. Therefore, we need to find efficient supportive strategies in order to be able to exploit the degeneration-induced neurogenic response at a clinical level. Current cell approaches focus on two predominant modalities: stimulation of the endogenous NSC niche and transplantation of exogenous stem cells. The former approach aims at stimulating the proliferation, migration, and persistence of brain NSCs. Lessons on this topic can be learned from studies on the post-ischemic brain. After stroke, newborn cells from the dentate gyrus and the subventricular zone travel along blood vessel scaffolds and relocate to areas of damage in order to replace dying neurons [19] . However, only 20% of migrating newborn cells successfully complete the integration process [20] . Failed integration and progenitor death may also be linked to inefficient neurogenesis in MNDs. Several strategies to increase neurogenesis after ischemic stroke have been attempted in experimental models. Selective serotonin reuptake inhibitors, statins, and ascorbic acid have been shown to increase NSC proliferation and migration and to improve functional outcome after experimental ischemic stroke in animal models [21] [22] [23] .
As an alternative to promoting endogenous neurogenesis, other cellular types, such as astrocytes, could be reprogrammed into NSCs in vivo by cocktail of NSCs or neuronal transcription factors [24] . However, this fascinating approach is still in its technological infancy.
Neural Stem Cells and Motor Neuron Diseases: Cell Transplantation
The exogenous approach is based on the transplantation of NSCs obtained from different external sources to the CNS. This strategy has already been applied in murine models of different MNDs, namely, ALS [25] [26] [27] , SMA [28, 29] , and SMA with respiratory distress (SMARD1) [28, 30] . Advances in stem cell biology and the use of adult somatic cells reprogrammed into induced pluripotent stem cells (iPSCs) as a possible source of NSCs have fostered basic and preclinical research in stem cell transplantation therapy [25] .
Exogenous NSCs may act through a process of cellular replacement, migrating and engrafting into damaged tissues [31, 32] . However, the therapeutic effect elicited by NSCs extends beyond the replacement of injured cells. Transplanted NSCs in experimental MNDs exert trophic and immunomodulatory actions and increase host brain neural plasticity [25, 31, 32] . NSCs may lead to environmental enrichment by releasing trophic factors, scavenging toxic ones, promoting neoangiogenesis, or forming novel neural circuitries around diseased areas, eventually favoring the recovery of the injured CNS [25, 31, 32] . NSCs can also differentiate into non-neuronal progeny (oligodendrocytes, astrocytes) known to promote homeostasis and support regenerating host axons [31] . Indeed, NSCs can also elicit protection or regeneration of perilesional tissues and circuitries [31, 33] . In the past ten years, several preclinical studies focusing on the use of stem cells in ALS transgenic animal models have shown promising results [26, 27, 31, [34] [35] [36] [37] . Furthermore, Teng and colleagues demonstrated an increased therapeutic effect when performing multiple dose-escalating injections in different CNS sites, indicating the importance of administering enough cells into critically functional areas to hinder ALS-induced damage [31] .
Our group recently demonstrated that isolating a specific NSC subpopulation that expresses certain surface antigens allows the employment of a discrete cellular population with stronger therapeutic effects on ALS disease models.
Indeed, we described that transplantation of iPSC-derived LewisX + CXCR4 + β1-integrin + NSCs slows motor neuronal degeneration and preserves muscle innervation in ALS human and rodent models [27] . The subpopulation positive for LewisX-CXCR4-β1-integrin protects neurons from early degeneration and enhances axonal elongation of human ALSderived motor neurons cocultured with toxic ALS astrocytes, through inhibiting neuronal disease mechanisms (GSK3-b pathway) and blocking astrocyte activation. In vivo, this NSC subpopulation promotes neuromuscular junction integrity, induces novel axonal sprouting, and diminishes macroand microgliosis, with an overall improvement in survival and neuromuscular function in transplanted SOD1G93A mice. These results suggest that modulating multiple diseased pathways in both neuronal and glial cells could effectively increase the preservation of muscular functional innervation [27] .
The first safety clinical trial of direct intraspinal delivery of fetal-derived NSCs into ALS patients was approved in 2009 and has now undergone phase 2 [38] [39] [40] [41] . The results showed that intraspinal stem cell transplantation can be safely performed at high doses and does not accelerate disease progression. Outcome analysis of the phase 1/2 studies demonstrated significantly improved survival and function in comparison to that in historical datasets [42] . However, despite the encouraging results, the potential biases connected with historical controls underline the limitations of non-controlled studies and post hoc analyses, thereby stating the need for efficacy studies and sufficiently powered and randomized clinical trials.
Unfortunately, a major hurdle to successful regenerative therapy is the limited survival of transplanted cells, partly because of immunological graft rejection [43] . A postmortem study of graft survival conducted on six trial patients revealed that transplanted NSCs survived up to 2.5 years, some differentiating into neurons, while others maintained their stemness [44] . Notwithstanding these findings, several elements contribute to the rejection of transplanted stem cells in ALS. For instance, ALS progression is characterized by a concomitant multiphase immune activation, which actively shapes disease pathology and pathogenesis [45, 46] . Likewise, the inevitable inflammation and local trauma resulting from invasive cell transplantation surgery could compromise the survival of injected cells [25] . Furthermore, the neurodegenerating environment can influence stem cell endurance. In a recent experiment, murine NSCs genetically modified to express firefly luciferase were transplanted into the cervical spinal cord of presymptomatic mutant SOD1 mice [47] . A transient improvement in locomotor function was witnessed only at early disease stages, whereas in the subsequent weeks, a sharp decline in bioluminescent imaging was found, with a complete signal loss at the endpoint. Macrophage activation, astrogliosis, and microgliosis were also noted in proximity to the transplantation site. Conversely, the bioluminescent signal intensity persisted in injected healthy controls throughout the entire study period. Thus, disease progression seems to jeopardize the survival of transplanted NSCs because of the progressive formation of a toxic spinal cord microenvironment [47] . Exposure to a hostile environment might hinder grafted NSC survival and therapeutic effects not only through the generation of toxic by-products but also by increasing their susceptibility to immune targeting. Indeed, although grafted NSCs elude immune targeting by expressing low levels of major histocompatibility complex (MHC) antigens, proinflammatory cytokines such as interferon γ may result in the upregulation of MHC expression [48] .
These findings further highlight the challenges that researchers need to overcome in order to develop a successful stem cell engraftment strategy.
Engineering Strategies to Enhance NSC Survival and Therapeutic Effects
Survival of NSCs after transplantation is the prerequisite for their therapeutic effect in host tissues. However, because of the aforementioned pathological microenvironment present in MNDs and other neurodegenerative diseases, the majority of grafted NSCs undergo cell death upon transplantation [49] , thus making targeted stem cell manipulation to foster survival an essential target for intervention. To this aim, different techniques have been developed, such as hypoxic or pharmacological preconditioning [50] , seeding of NSCs within biomaterial scaffolds, and genetic manipulation of cells prior to transplantation [51] (Fig. 1 ).
Hypoxic Preconditioning
Ischemic or hypoxic preconditioning treatments have been shown to promote tolerance and regenerative properties of transplanted stem cells, increasing their resistance to low substrates and oxygen availability in degenerating tissue via adaptive responses such as the upregulation of anti-apoptotic genes (Bcl-2, HIF-1) and reduction in caspase-3 activity (Table 1 ) [50] . Additionally, NSCs have been hypothesized to be physiologically predisposed to anaerobic/microaerophilic metabolic patterns, which enhance self-renewal and inhibit differentiation [52] . Therefore, exposure of the cells to highly aerobic conditions, such as atmospheric oxygen, before transplantation might unwillingly compromise their survival once injected into neural tissues, especially the hypoxic/anoxic environment typical of neurodegenerative diseases [52] . Moreover, hypoxic preconditioning of transplanted NSCs has been shown to enhance the therapeutic properties of NSCs via neurotrophic secretion. Indeed, controlled hypoxia (1% O 2 for 4 h) upregulates HIF-1α, neurotrophic, and growth factors including neurotrophin-3 (NT-3), glial cellderived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF) [53] . Hypoxic preconditioning promotes increased expression of HIF1-α and HIF target genes such as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), but the direct molecular mechanisms of induction of other neurotrophic factors are unknown.
In another study, Wakai and colleagues further demonstrated that mild hypoxia (5% O 2 for 24 h) also promotes NSC proliferation and resilience to transplantation by upregulating phospho-Akt (pAkt) expression via HIF-1α and subsequent expression of VEGF [33] . Akt is well known to contribute to self-renewal and differentiation in NSCs. Thus, modulating pAkt levels may directly contribute to the increase in survival of transplanted cells.
Overall, these findings suggest that hypoxic preconditioning strategies promote survival of transplanted cells, increase their neuroprotective properties, and facilitate functional recovery in in vivo models of neurological diseases (Table 1) . Notably, although HIF-1α and their downstream pathways appear crucial, the precise cellular mechanisms activated by hypoxic preconditioning have not been clarified yet. Direct pharmacological modulation of HIF-1α could be a potential target to directly obtain the beneficial effects of hypoxic preconditioning.
To further elucidate the molecular mechanisms underlying hypoxic preconditioning, a recent study analyzed the microRNA expression profiles of exosomes derived from normal vs hypoxic preconditioned NSCs by next-generation sequencing [54] . After hypoxic preconditioning, the exosomal miRNA expression profile was modified, and some miRNAs were differentially expressed in the two populations, such as miR-98-3p. Exosomal functions changed as well, and exosomes from preconditioned cells appeared capable of modulating gene expression and promoting stroke recovery [54] . Notably, this work reveals how the administration of exosomes derived from preconditioned cells could represent an alternative approach to direct NSC transplantation, thus avoiding the risks related to the use of a cellular product.
Pharmacological and Small-Molecule Preconditioning
Furthermore, pharmacological preconditioning strategies have also been studied ( Table 2 ). NSCs exposed to minocycline have been observed to display upregulation of Nrf2, a transcription factor that regulates the basal and inducible expression of a spectrum of antioxidant genes and the secretion of neurotrophic factors, including BDNF, nerve growth factor (NGF), GDNF, and VEGF, thereby enhancing functional recovery in vivo [55] . The positive effects of minocycline preconditioning, as well as the simplicity and lack of safety concerns, make this strategy highly suitable for future clinical applications.
Similarly, exposure to interleukin-6 (IL-6) has been demonstrated to increase expression of manganese superoxide dismutase (SOD2), a primary mitochondrial antioxidant enzyme, through signal transducer and activator of transcription 3 (STAT3), thus making transplanted NSCs more resistant to oxidative stress in both in vitro and in vivo settings [56] . Indeed, IL-6 stimulation promoted secretion of VEGF from NSCs [56] . The simplicity of the use of minocycline makes it interesting for clinical translation.
Among pretreatments with neurotrophins, BDNF-treated NSCs were shown to result in higher NSC engraftment and survival, increased neuroprotection, and greater functional outcomes in a stroke model when compared to untreated NSCs [57] . Remarkably, BDNF pretreatment promoted expression of chemokine receptors and adhesion molecules, thereby favoring not only cerebral engraftment but also migration. In addition, BDNF pretreatment of NSCs stimulated the secretion of neuroprotective peptides. Therefore, BDNF treatment of NSCs is a simple strategy that can be used to increase engraftment success.
Another small molecule tested for preconditioning is adjudin, which is currently under study as a potential nonhormonal male contraceptive, given its ability to disrupt the adherens junction between germ cells and Sertoli cells without affecting testosterone production [58] . This molecule has been suggested to be neuroprotective in stroke models [59] . For this reason, pretreatment of NSCs with adjudin was attempted, resulting in intracellular inhibition of oxidative damage, activation of the NSC pro-survival Akt signaling pathway, and increased expression of BDNF, NGF, and GDNF after treatment, thereby promoting NSC survival after transplantation into an ischemic area [60] .
Preconditioning can increase not only survival but also other proliferation and migration properties of NSCs. High-mobility group box 1 (HMGB1) is an inflammatory protein that exerts beneficial effects in the chronic phase following CNS injury [61] . Furthermore, HMGB1 was shown to promote NSC proliferation in vitro; thus, HMGB1 may be exploited as a preconditioning molecule. Exposure of NSCs to HMGB1 before transplantation was found to stimulate not only NSC proliferation but Fig. 1 Engineering strategies to increase stem cell engraftment and survival within the host tissue include hypoxic and pharmacological (minocycline, adjudin, interleukin-6, BDNF) preconditioning, seeding of cells into biomaterial scaffolds, and genetic manipulation to overexpress neurotrophic or survival genes. When transplanted into the CNS, treated cells show reduced death rates and increased proliferative abilities. Furthermore, they display enhanced neuroprotective properties, increasing endogenous neuroblasts proliferation and migration and reducing infarct size and reperfusion-induced injury in experimental models. In addition to that, engineered cells appear able to increase expression of anti-apoptotic (HIF1a, Bcl-2), antioxidant (iNOS, SOD2, catalase, Nrf2), and trophic (VEGF, EPOR) genes. Remarkably, they can also promote the secretion of neurotrophic factors (GDNF, BDNF, VEGF, NGF, NT-3) and reduce cytokine production and microglial activation also migration [61] . Therefore, targeted HMGB1 preconditioning before transplantation could enhance NSC relocalization within diseased areas of the CNS [61] .
Recently, NSC pretreatment with metformin, an approved antidiabetic compound, was investigated, following the observation of a potential pro-neurogenic effect of this substance [62] . Pretreatment of human iPSC-derived NSCs with metformin enhanced both their proliferation and their differentiation in culture. Moreover, metformin-preconditioned NSCs displayed an increased engraftment with better functional outcomes in rodent stroke models. Interestingly, this strategy promoted not only cell survival but also differentiation, a useful property for clinical application.
A possible preconditioning approach that has not been investigated yet involves the use of small molecules that interfere with regulated necrosis, through substances able to modulate key enzymes of these pathways [63] . These compounds include necroptosis inhibitors such as necrostatin-1 (Nec-1) and newer molecule such as ferrostatins. This approach warrants investigation in the context of NSC transplantation.
Although whether such artificial approaches could ultimately prove relevant at a clinical level remains unclear, translational research may be advantageous due to the simple, transient, and non-integrative nature of these techniques. Additionally, the simultaneous use of several combined small molecules acting on different pathways could be explored. On the other hand, the limitations of these approaches reside on their short and temporary effect.
Use of Scaffolds in NSC Transplantation
A further innovative technique to support NSC survival and engraftment is represented by the transplantation of cells included in natural or synthetic bioengineered scaffolds. These scaffolds aim to create a more favorable environment for transplanted cells with respect to the native host tissue, thereby facilitating manipulation and transplantation phases and reducing mechanical stress.
For instance, transplanting NSCs seeded within a biopolymer hydrogel matrix was recently shown to improve the durability and performance of the graft in the host tissue [64] . The hydrogel was composed of cross-linked hyaluronan and heparin sulfate, mimicking the CNS extracellular matrix, and significantly promoted NSC engraftment after transplantation. [33]
Primary rat NSCs exposed to 1% O 2 for 2, 4 or 6 h Rat, stereotaxic SCI During procedure; intraspinal, in situ ↑ locomotor recovery. ↑ neuronal survival and reduced glial scar formation. ↑ expression of GDNF, BDNF, NT-3, and HIF1alpha.
[53]
Abbreviations: BDNF, brain-derived neurotrophic factor; BMSCs, bone marrow mesenchymal stem cells; EPO, erythropoietin; EPOR, erythropoietin receptor; ESCs, embryonic stem cells; GDNF, glial-derived neurotrophic factor; ICH, intracerebral hemorrhage; iPSCs, induced pluripotent stem cells; NF, neurofilament; NPCs, neural progenitor cells; NSCs, neural stem cells; NT-3, neurotrophin-3; SCI, spinal cord injury; TBI, traumatic brain injury; tMCAO, transient middle cerebral artery occlusion; VEGF, vascular endothelial growth factor Such hydrogel matrices could also be Bfunctionalized.F or instance, Adil and colleagues supplemented a hyaluronic acid hydrogel with arginylglycylaspartic acid and heparin via click chemistry and tailored its stiffness to improve neuronal cell graft survival [65] . Cells were cultured and harvested within the scaffold to reduce mechanical and enzymatic stress. Remarkably, after transplantation, hydrogel-encapsulated cells had a fivefold higher survival rate than unencapsulated donor cells, suggesting that the bioscaffold approach can greatly improve transplantation efficacy.
Furthermore, scaffolds can be used as a depot release for growth factors to promote transplant stem cell survival and differentiation. Moshayedi and colleagues engineered a hyaluronic acid-based self-polymerizing hydrogel by inserting growth factors, BNDF or BMP-4, and heparin into the hyaluronic acid backbone in order to promote their retention [66] .
Recently, Soma and his team developed an injectable biological substrate that self-assembles within the host tissues from a laminin-derived epitope, thereby mimicking the brain's major extracellular protein, supporting long-term survival and functional maturation of NSCs [67] . Remarkably, scaffolds assembled with conductive polymers were shown to allow electrical stimulation of NSCs before transplantation, with enhanced functional recovery [68] . This strategy is based on a combination of the scaffolding technology with preconditioning treatment. Electrical stimulation of human NSCs changes the expression pattern of genes, in particular VEGF-A pathway genes and genes involved in cell survival. Upon transplantation, electrically preconditioned NSCs more effectively improved functional outcomes in animal models than did unstimulated NSCs. The use of scaffolds to influence the NSC transcriptome provides an additional opportunity to optimize NSC-based approaches.
Overall, these findings suggest that acting on the local environment promotes the success and efficacy of NSC transplantation. This evidence advocates for the refinement of scaffolding technology in order to boost the therapeutic arsenal of stem cell-based regenerative medicine. [60]
Abbreviations: BDNF, brain-derived neurotrophic factor; ESCs, embryonic stem cells; GDNF, glial-derived neurotrophic factor; iNOS, inducible nitric oxide synthase; IL-6, interleukin-6; NGF, nerve growth factor; NSCs, neural stem cells; tMCAO, transient middle cerebral artery occlusion; VEGF, vascular endothelial growth factor
Ex Vivo Genetic Modification to Increase NSC Engraftment
Ex vivo genetic engineering could also be exploited to tune the expression of genes involved in NSC function in order to tailor the NSC proteome and secretome to the therapeutic needs of MNDs [69] . Indeed, in addition to graft survival, gene therapy could also be used to maximize the therapeutic potential of NSCs by selectively altering their secreted products [69] . NSCs genetically modified to overexpress different neurotrophic genes (GDNF, BDNF, neurotrophin-3, NGF) have shown improved survival rates and enhanced proliferative and neuroprotective properties in the context of neurological diseases and MNDs [70] [71] [72] [73] [74] [75] [76] . In a recent study, human cortical-derived NSCs were engineered to secrete GDNF and transplanted into the SOD1G93A ALS rat cortex [76] . The cells were able to migrate and differentiate mainly into GDNF-producing astrocytes. This treatment resulted in the preservation of motor neurons and amelioration of disease pathology. These NSCs administered into the cortex of nonhuman primates survived and presented robust GDNF expression without adverse effects. This study suggests a synergic effect of GDNF and NSC transplantation and the superiority of this combined approach compared to the effects of GDNF or NSC treatment alone shown in previous studies. Thus, the transplantation of genetically modified stem cells represents a possible therapeutic strategy for MNDs to be further explored. In addition to genetic modification of growth factors, overexpression of SOD2 to lower free radicals reduces NSC death rates after transplantation in a stroke model and suppresses the generation of reactive oxygen species after reperfusion injury [77] . Thus, other candidate genes could be explored for ex vivo genetic modifications of NSCs prior to transplantation. Strikingly, while previous studies focused on the selective manipulation of distinct genes or proteins in NSCs, recent discoveries have highlighted manifold processes, such as global SUMOylation, which appear to protect cell homeostasis against ischemia-induced stress [78] . Achieving a wider spectrum of favorable biological modifications in NSCs may prove more effective than acting on singular molecular aspects. Therefore, future studies could target a variety of these mechanisms simultaneously in order to boost the regenerative and neuroprotective potential of NSC-based transplantation therapies.
Translational Perspectives for Engineering Techniques
Despite the enormous potential of stem cell-mediated therapy for MNDs, some crucial issues still need to be addressed before allowing extensive clinical translation. NSC engineering techniques could represent a powerful aid to overcome some of these obstacles.
First, the appropriate delivery method of cells within the CNS should be optimized and standardized. In this regard, assessments and comparisons of the exact potential of different scaffolding strategies and their clinical tolerability could prove useful. Both biodegradable and non-biodegradable materials have been studied, but their safety and efficacy profile in humans has not been assessed yet. As discussed above, scaffolding techniques greatly improve the engraftment rate and may also be exploited to reduce the cellular stress connected with cell delivery. Second, confirmation of graft survival is essential to determine treatment efficacy. In many animal models, this identification is obtained through immunohistochemical identification with human-specific markers [25] . Upon clinical translation, more sophisticated techniques are needed to assess this aspect. Genetic engineering techniques could allow the detection of grafted cells, for instance through the expression of radiotracers. Another option is the use of MRI-trackable scaffolds [66] .
Reduced survival of engrafted cells is a further hindrance to transplantation success. Hypoxic preconditioning and pharmacological preconditioning have proven efficient in increasing cell resilience to delivery stress and triggering expression of pro-survival genes (Tables 1 and 2 ). Furthermore, cells engineered to express neurotrophic factors or antioxidant genes displayed an enhanced survival rate in preclinical studies [76, 77] . Therefore, these strategies, combined with the use of proper scaffolds, could help address these challenges. To allow clinical translation, however, safety and immunogenicity in humans need to be assessed.
Another crucial issue is represented by the oncogenic potential of transplanted cells, in particular when they are genetically modified to increase their survival. A viable strategy to overcome this issue involves the use of partially or fully differentiated cells, such as neural precursors or adult neurons, with limited proliferative capacity. Another technique to avoid neoplastic complications is represented by genetic manipulation of stem cells in order to suppress growth promoters or to insert specific genes, which can trigger apoptosis upon specific stimulation [25] . In this way, transplanted cells could be selectively targeted by cytotoxic drugs in case they undergo neoplastic transformation.
To summarize, stem cell engineering techniques are still in their infancy, but they present a striking potential for maximizing the beneficial properties of NSCs in neurological disorders. Although we are still far from their clinical application, further development of these approaches is warranted in order to expand the horizons of transplantation therapy.
Conclusions and Future Perspectives
Currently, despite extensive research efforts, no successful treatment for MNDs is available. Nonetheless, preclinical studies on stem cell-based transplantation therapy have yielded significant and interesting results, showing neuroprotective effects, improved functional outcomes, and delayed progression in treated groups [26, 27, 31, [34] [35] [36] [37] . The main limitation of this approach in regard to clinical translatability is the low engraftment success and the high rate of stem cell death following transplantation. Therefore, there is a strong need for strategies aimed at addressing the issue of NSC viability and stability after transplant. Several approaches have been investigated thus far, namely, environmental stress preconditioning, biopolymer encapsulation, and genetic engineering, showing beneficial effects not only on graft integration and survival but also on the neuroprotective and immunomodulatory effects of NSCs (Fig. 1) [70] [71] [72] [73] [74] [75] [76] [77] . Different approaches can be combined to further enhance their effects.
Nevertheless, additional studies are needed to precisely understand the molecular mechanisms that regulate cell survival after transplantation. Among the mechanisms that were identified, the hypoxic response cascade and Akt pathways appeared crucial. Moreover, the increased therapeutic effects of different preconditioning strategies seem to be due to the increased capacity of NSCs to produce and secrete neurotrophic molecules, further highlighting the importance of paracrine factors and the microenvironment in stem cell engraftment.
Hopefully, future studies on NSC transplantation will exploit these engineering techniques in the quest for a more stable and effective cellular graft. A better understanding of the pathways involved in cellular homeostasis and in the cellular response to environmental insults, such as those leading to neurodegeneration, may suggest further potential targets for manipulation, with the aim of counteracting the cytotoxic mechanisms of neurodegenerative diseases.
